Skip to Content
Merck
  • Modulating drug release from gastric-floating microcapsules through spray-coating layers.

Modulating drug release from gastric-floating microcapsules through spray-coating layers.

PloS one (2014-12-04)
Wei Li Lee, Jun Wei Melvin Tan, Chaoyang Nicholas Tan, Say Chye Joachim Loo
ABSTRACT

Floating dosage forms with prolonged gastric residence time have garnered much interest in the field of oral delivery. However, studies had shown that slow and incomplete release of hydrophobic drugs during gastric residence period would reduce drug absorption and cause drug wastage. Herein, a spray-coated floating microcapsule system was developed to encapsulate fenofibrate and piroxicam, as model hydrophobic drugs, into the coating layers with the aim of enhancing and tuning drug release rates. Incorporating fenofibrate into rubbery poly(caprolactone) (PCL) coating layer resulted in a complete and sustained release for up to 8 h, with outermost non-drug-holding PCL coating layer serving as a rate-controlling membrane. To realize a multidrug-loaded system, both hydrophilic metformin HCl and hydrophobic fenofibrate were simultaneously incorporated into these spray-coated microcapsules, with metformin HCl and fenofibrate localized within the hollow cavity of the capsule and coating layer, respectively. Both drugs were observed to be completely released from these coated microcapsules in a sustained manner. Through specific tailoring of coating polymers and their configurations, piroxicam loaded in both the outer polyethylene glycol and inner PCL coating layers was released in a double-profile manner (i.e. an immediate burst release as the loading dose, followed by a sustained release as the maintenance dose). The fabricated microcapsules exhibited excellent buoyancy in simulated gastric fluid, and provided controlled and sustained release, thus revealing its potential as a rate-controlled oral drug delivery system.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrochloric acid, 36.5-38.0%, BioReagent, Molecular Biology
Supelco
Hydrochloric acid solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Fenofibrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Hydrochloric acid, ACS reagent, 37%
Sigma-Aldrich
Hydrochloric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., fuming, ≥37%, APHA: ≤10
USP
Fenofibrate, United States Pharmacopeia (USP) Reference Standard
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Hydrochloric acid solution, 32 wt. % in H2O, FCC
Supelco
Hexane, analytical standard
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Hexane, anhydrous, 95%
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Piroxicam, European Pharmacopoeia (EP) Reference Standard
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hexane, ReagentPlus®, ≥99%
Sigma-Aldrich
Hexane, suitable for HPLC, ≥95%
Sigma-Aldrich
Hexane, suitable for HPLC, ≥97.0% (GC)
Sigma-Aldrich
Hexane, HPLC Plus, for HPLC, GC, and residue analysis, ≥95%